Translating potent SARS-Cov-2 neutralising nanobodies from the lab to the clinic

目前还没有治愈新冠肺炎的方法。然而，使用阻止SARS-CoV2感染细胞的抗体治疗可能会阻止或改善疾病。我们已经生产出非常有效的微型抗体或纳米抗体，在“试管”实验中以100%的效率中和病毒。纳米体内的小尺寸和稳定性使它们成为使用雾化设备直接进入肺部的候选对象，其想法是快速减少呼吸道感染。我们已经产生的高度中和SARS-Cov2纳米抗体已经准备好进行动物试验。在动物身上成功展示活性将是开发这种用抗体治疗Covid19的新方法的关键一步。

There is currently no cure for Covid-19. However, treatment with antibodies that block SARS-CoV2 from infecting cells may halt or ameliorate disease. We have produced very potent mini-antibodies or nanobodies that neutralise the virus in "test-tube" experiments with 100 % efficiency. The small size and stability of the nanobodies make them candidates for direct delivery into the lungs using a nebuliser device with the idea of rapidly reducing infection in the airways. The highly neutralising SARS-Cov2 nanobodies that we have generated are ready for animal tests. Successful demonstration of activity in animals will be the key step to developing this novel way of treating Covid19 with antibodies.